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An exclusive feature of dendritic cells (DCs) is their ability to cross-present exogenous
antigens in MHC class I molecules. We analyzed the fate of protein antigen in antigen
presenting cell (APC) subsets after uptake of naturally formed antigen-antibody com-
plexes in vivo. We observed that murine splenic DC subsets were able to present antigen
in vivo for at least a week. After ex vivo isolation of four APC subsets, the presence of
antigen in the storage compartments was visualized by confocal microscopy. Although all
APC subsets stored antigen for many days, their ability and kinetics in antigen presenta-
tion was remarkably different. CD8α+ DCs showed sustained MHC class I-peptide specific
CD8+ T-cell activation for more than 4 days. CD8α− DCs also presented antigenic peptides
in MHC class I but presentation decreased after 48 h. In contrast, only the CD8α− DCs
were able to present antigen in MHC class II to specific CD4+ T cells. Plasmacytoid DCs
and macrophages were unable to activate any of the two T-cell types despite detectable
antigen uptake. These results indicate that naturally occurring DC subsets have func-
tional antigen storage capacity for prolonged T-cell activation and have distinct roles in
antigen presentation to specific T cells in vivo.
Keywords: Antigen presentation/processing  CD4 T cells  CD8 T cells  Cross presenta-
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Introduction
Dendritic cells (DCs) are professional antigen presenting cells
(APCs) that can capture, process and present exogenous anti-
gen on MHC class I (MHCI) molecules. This cross-presentation
pathway is considered to be a specialized function of DCs. We
have previously demonstrated that the uptake of the protein anti-
gen ovalbumin (OVA) bound to OVA-specific IgG antibodies, also
called OVA immune complexes (OVA IC), by DCs is at least 100-
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fold more efficient than uptake of free OVA (1). This antibody-
dependent uptake route of OVA IC results in DC maturation, spe-
cific CD8+ T-cell priming and tumor protection in vivo [2, 3].
Moreover, we have reported that DCs can store OVA IC for many
days in a lysosome-like organelle, distinct from MHC class II com-
partments or MHCI processing/ loading compartments. Despite
the rapid turnover rate of MHCI-peptide complexes on the cell
surface, this storage compartment serves as an antigen source for
continuous supply of MHCI ligands and thereby enhancing sus-
tained cross-presentation to CD8+ T cells [1].
Lymphoid organs harbor different DC subsets in vivo and
their role in antigen presentation have been studied extensively.
The secondary lymphoid organs in mouse contain two main DC
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subtypes: plasmacytoid DCs (pDCs) and conventional DCs (cDCs).
In murine spleen, resident cDCs can be further subdivided into
CD8α+ DCs and CD8α− DCs based on the expression of a wide
variety of surface markers [4, 5]. Although both cDC subsets have
the ability to take up and present exogenous antigens on MHCI,
CD8α+ DCs are known for their specialized and much more effi-
cient cross-presentation of cell-associated, antibody-bound, or sol-
uble antigen to CD8+ T cells in vivo and ex vivo [6–11]. On the
other hand, CD8α− DCs preferentially present antigen on MHCII
to CD4+ T cells to a greater extent than CD8α+ DCs.
In the current study we injected mice sequentially with anti-
OVA IgG and OVA to form OVA IC in vivo. We have previ-
ously demonstrated that this natural formation of antigen-IgG
complexes in vivo leads to efficient antigen cross-presentation to
CD8+ T cells in which C1q plays an important role [12, 13]. Four
APC subsets from murine spleen were studied here: CD8α+ DCs,
CD8α− DCs, pDCs andmacrophages. We show that all APC subsets
were able to take up and store antigen for several days in vivo.
However, their ability and kinetics in antigen presentation was
remarkably different. CD8α+ DCs showed more efficient MHCI
cross-presentation to CD8+ T cells for several days compared to
CD8α− DCs. Only CD8α− DCs showed effective and prolonged
MHCII presentation to CD4+ T cells. Despite detectable uptake of
antigen, pDCs and macrophages were incapable to activate T cells.
Our results show for the first time that naturally occurring DC sub-
sets have functional compartments to store antigen for prolonged
T-cell activation in vivo and each DC subset appears to play a dis-
tinct role in their antigen presentation function to specific T cells.
Results
Long lasting MHCI and MHCII antigen presentation
in vivo
We previously reported that DCs have the ability to conserve
exogenous protein antigen for several days in intracellular anti-
gen containing compartments which facilitate prolonged antigen
cross-presentation to CD8+ T cells [1]. This specialized function
of DCs has primarily been shown using cultured dendritic cells
in vitro. To analyze the capacity and duration of naturally occur-
ring APC subsets to present antigen to CD8+ and CD4+ T cells in
vivo, na¨ıve C57BL/6 mice were first intravenously injected with
OVA-specific IgG antibody and after a recovery period of 30 min
followed by an i.v. injection of OVA protein antigen (Fig. 1A).
Separate injection of antibody followed by antigen will allow nat-
ural formation of antigen-antibody immune complexes (IC). Anti-
gen presentation in vivo was analyzed by injecting OVA-specific
transgenic CD8+ and CD4+ T cells, OTI or OTII cells respectively,
several time points after OVA antigen administration. Twenty four
hours after IgG and OVA injection strong CD8+ and CD4+ T-cell
proliferation was observed (Fig. 1B). Mice injected with only OVA
did not activate either of the T-cell subsets, underlining the effi-
ciency of antibody-mediated targeting of soluble protein. Mice that
received OTI cells 24 h after IgG and OVA injection showed90%
T-cell proliferation. This effect hardly diminished in time to80%
after 4 days and even one week after IgG and OVA injection 30–
40% of the CD8+ T cells still proliferated (Fig. 1C). The same we
observed for OTII CD4+ T-cell proliferation. Although the prolifer-
ation of CD4+ T cells decreased faster in time compared to CD8+
T cells, there was still some activity detected after 1 week. These
results show that in vivo formed antigen-antibody complexes are
efficiently presented to CD8+ and CD4+ T cells for at least a week
suggesting that antigen is stored in APCs for many days.
Effective and sustained cytotoxic T-cell killing
capacity
Beside the prolonged antigen presentation in vivo, we determined
whether these antigen containing resident APCs were able to
induce functional CD8+ T cells with killing capacity. C57BL/6
mice that have been injected with OVA specific antibody followed
by OVA antigen received OTI T-cell adoptive transfer after 48 h
or 1 week (Fig. 2A). The induction of effector CD8+ T cells was
determined by the decrease of CD127+ (IL-7Rα) and the increase
of CD44+ expression on OTI T cells (data not shown). To deter-
mine whether these T cells were able to kill specific target cells in
vivo, splenic target cells were loaded with OVA peptide or control
peptide and injected in mice 4 days after OTI adoptive transfer.
The next day, in vivo killing of target cells was analyzed in the
spleen. Mice that received anti-OVA antibody and OVA, 48 h prior
to the OTI adoptive transfer, showed near 80% specific killing and
a higher percentage of OTI cells of total CD8+ T cells compared
to mice that only received OVA (Fig. 2B). Mice that were injected
with OTI cells 1 week after they first received anti-OVA antibody
and OVA also showed higher numbers of OTI cells with almost
60% specific killing of the target cells and no detectable killing
in mice that only received soluble OVA (Fig. 2C). Similar results
were found when in vivo killing of target cells was analyzed in the
lymph nodes derived from the samemice (Supporting Information
Fig. 1).
APC subsets take up and store antigen for several
days in vivo
We have previously shown that CD11c+ cells are crucially involved
in antigen presentation of in vivo complexed antigen [12]. Since
we observed prolonged T-cell activation, proliferation and killing
capacity above, we set out to determine which APC subsets
play a role in sustained antigen storage in vivo. Four sub-
sets in the spleen of mice were distinguished by the following
markers: CD8α+ DCs (CD11chigh CD8α+ CD11b−), CD8α− DCs
(CD11chigh CD8α− CD11b+), pDCs (CD11cint Ly6C+ B220+) and
macrophages (CD11cint CD11b+ F4/80+) using flow cytometry
(Fig. 3A). The major population is the macrophages (3% of total
spleen cells), followed by CD8α− DCs (2%), CD8α+ DCs (1%)
and pDCs (<0.5%). Mice were injected sequentially with anti-OVA
IgG antibody and Alexa Fluor 647 labeled OVA to track the uptake
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Figure 1. Sustained T-cell proliferation in vivo. C57BL/6 (BL/6) mice were i.v. injected with anti-OVA IgG (Ab) followed by OVA i.v. injection 30 min
later. At different time points mice were i.v. injected with CFSE-labeled spleen cells from OTI or OTII mice. Spleens were then collected after 4
days and analyzed by flow cytometry (A). OTI (CD8+/ CD90.1+ cells) and OTII (CD4+/ CD45.1+ cells) proliferation analysis (percentages indicated)
from the spleens of mice that received OVA and Ab or OVA only injections for 24 h (B), and percentage proliferated T cells of three mice per group
indicated for all time points (24 h/48 h/72 h/96 h/1 week) combined (C). Flow cytometry data are from a single experiment with three mice per
group, representative of two experiments.
in the APC subsets. Approximately 6% of the CD8α+ DCs were
antigen positive after 12 h of antibody and OVA injection (Fig. 3B
upper panel, Supporting Information Fig. 2A). This remains sus-
tained in time up to 72 h where 2% antigen positive CD8α+ DCs
were found in the spleen (Fig. 3B upper panel). A similar pat-
tern of sustained antigen presence in time was found in the other
APC subsets. Measuring the mean Alexa 647 fluorescence intensity
(MFI) of the subsets showed less than 50% decrease from 12 h up
Figure 2. Sustained induction of cytotoxic T-cell activity in vivo. BL/6mice were injected i.v. with Ab followed 30min later by OVA i.v. injection (A).
After 48 h (B) or 1week (C),mice received i.v. adoptive transfer of OTI cells, followed by target cells 4 days later. OTI cell (CD8+/ CD90.1+) proliferation
and specific cytotoxic killing of target cells were measured overnight by spleen analysis. Data are from a single experiment representative of three
experiments with each dot representing one mouse. **p < 0.01, ***p <0.001.
C© 2018 The Authors. European Journal of Immunology published by
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Figure 3. Sustained antigen presence in APC subsets in vivo. Four splenic APC subsets in BL/6 mice were distinguished by the following markers
in flow cytometry: CD8α+ DCs (CD11chigh CD8α+ CD11b−), CD8α− DCs (CD11chigh CD8α− CD11b+), pDCs (CD11cint Ly6C+ B220+) and macrophages
(CD11cint CD11b+ F4/80+) (A). BL/6 mice were injected with Ab i.v. followed by OVA (Alexa Fluor 647 labeled) i.v. injection 30 min later. Antigen
presence in spleens (each dot represents one mouse) was analyzed after 12 h/24 h/48 h/72 h, indicated by percentage positive cells and mean
fluorescence intensity (MFI) of Alexa Fluor 647 (B). Flow cytometry data are from a single experiment with three mice per group, representative of
four independent experiments.
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to 72 h after antibody and OVA injection (Fig. 3B lower panel).
Mice that only received OVA without antibody did not show any
detectable uptake indicating the efficiency of antibody-mediated
uptake of OVA (Fig. 3B, Supporting Information Fig. 2A). Similar
uptake with soluble OVA was only reached when 40 times more
OVA was given compared to antibody-mediated uptake (data now
shown).
Using an irrelevant antibody against HPV E6 protein we
observed no detectable antigen uptake by all APC subsets, indicat-
ing that antigen uptake is only achieved with the use of antigen
specific antibodies (Supporting Information Fig. 2B). To show that
this highly efficient antibody-mediated antigen uptakewas not due
to the use of rabbit specific IgG, mice were prime-boost vaccinated
with OVA protein to generate endogenous murine anti-OVA IgG
antibodies (Supporting Information Fig. 2C). Two weeks after the
booster vaccination, seropositive mice were injected with OVA
(Alexa Fluor 647 labeled) and efficient antigen uptake in all APC
subsets was detected (Supporting Information Fig. 2D). Moreover,
when serum fromOVA-vaccinatedmice, containing anti-OVA anti-
bodies, was transferred to na¨ıve mice followed by Alexa Fluor 647
labeled OVA injection, antigen uptake was detected in all APC sub-
sets in contrast to control mice (Supporting Information Fig. 2E).
Next we analyzed the presence of OVA protein in serum during
our experiments. A possible explanation for the sustained antigen
presence in APCs is that OVA protein is remaining in the circulation
of the mice which may allow continuous uptake of fresh OVA by
APCs over time. This is however an unlikely option since most
of the single injection of OVA was cleared from the circulation
already after 2 h and was non-detectable after 24 h (Supporting
Information Fig. 3). Taken together, these data demonstrate that
APC subsets in vivo have the ability to efficiently engulf and store
antigen in an antibody-dependent fashion for several days.
Antigen is stored in punctuated compartments in APC
subsets in vivo
In order to visualize and localize where antigen was stored in APC
subsets, all four subsets were sorted from the spleen at different
time points after the injection of anti-OVA antibody and Alexa
Fluor 647 labeled OVA and analyzed by confocal microscopy. An
overlay of the fluorescence signal and differential interference con-
trast (DIC) observed in optical slices from the ex vivo isolated
APC subsets show the location of antigen within the cells. After
12 h of antibody and OVA injection several intensely fluorescent
punctuated “hotspots” were found in all APC subsets (Fig. 4).
Co-staining with Lysotracker, a marker for endo-lysosomal com-
partments, showed partial co-localization with OVA indicating
intracellular localization and storage of antigen in DCs in endo-
lysosomal compartments (Supporting Information Fig. 4), simi-
lar as we described previously for DCs in vitro [1]. In general
the number of hotspots decreased in time in all four subsets but
remained detectable even after 72 h. These results are in line
with the MFI detection in Fig. 3B, indicating localized storage and
gradual decrease of antigen in time in these APC subsets in vivo.
Figure 4. Localization of antigen storage in APC subsets in vivo. BL/6
mice were injected with Ab i.v. followed by OVA (Alexa Fluor 647
labeled) injection after 30 min. Four APC subsets were sorted at dif-
ferent time points according to the markers described in Fig. 3A and
antigen presence in live cells was visualized by confocal microscopy.
Data are from a single experiment representative of three experiments
with two mice per experiment.
Sustained and selective MHC I and II antigen
presentation by CD8α+ and CD8− DCs
To address the question which APC subsets contributes to sus-
tained antigen presentation to CD8+ and CD4+ T cells, mice were
injected sequentially with anti-OVA antibody and OVA. At differ-
ent time points four APC subsets were separately sorted from the
spleen, as described before, and incubated ex vivo with either
CD8+ OTI or CD4+ OTII cells. Both CD8α+ DCs and CD8α− DCs
cross-presented antigen to OTI cells, with CD8α+ DCs being the
most potent cross-presenting subset (Fig. 5A). On the other hand,
CD8α− DCs were the only subset that could present antigen to
OTII cells. All four subsets that were isolated from spleens of mice
that were injected with the same dose of soluble OVA protein did
not show any detectable antigen presentation to either OTI or
OTII cells. Following the CD8α+ DC subset in time showed their
sustained capacity to cross-present antigen to OTI cells: 40% OTI
cells proliferated upon encountering CD8α+ DCs that had stored
antigen for 96 h (Fig. 5B). Although the CD8α− DCs were able
to cross-present antigen, it was in a lesser extent compared to
the CD8α+ DCs, e.g. only 10% OTI cells proliferated after being
exposed to CD8α− DCs that had stored antigen for 72 h. However,
the CD8α− DCs showed potent and sustained antigen presentation
to OTII T cells up to 72 h, whereas the CD8α+ DCs failed to do so
at any time point. In contrast, the pDCs and macrophages could
not present antigen to either OTI or OTII cells in any extent. Fig-
ure 5C shows significant higher antigen cross-presentation ability
of CD8α+ DCs compared to other APC subsets which was most
pronounced after 72 h. The CD8α− DCs was the only subset show-
ing significant and sustained antigen presentation to CD4+ T cells
C© 2018 The Authors. European Journal of Immunology published by
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Figure 5. Sustained and selective antigen presentation by splenic CD8α+ and CD8α− DCs. BL/6 mice (two mice per group) were injected with Ab
followed by OVA i.v. injection 30 min later. At different time points (12 h/24 h/48 h/72 h and 96 h), splenic APC subsets were isolated of individual
mice by FACS sorting according to the markers described in Fig. 3A and incubated with CFSE-labeled OTI (CD8+/ CD90.1+) or OTII (CD4+/ CD45.1+)
cells ex vivo for 3 days. CD8+ T-cell and CD4+ T-cell proliferation by APC subsets was measured in mice that received OVA and Ab or only OVA
for 24 h, indicated by the percentage of divided T cells (A). Percentage of CD8+ T-cell and CD4+ T-cell proliferation activated by APC subsets at all
time points is shown from one representative experiment out of three performed (B). Average proliferation data of three independent experiments
showing MHCI cross-presentation (upper panel) and MHCII antigen presentation (lower panel) by each APC subset after 24, 48 and 72 h (C). **p <
0.01, ***p <0.001, n.s: non-significant.
C© 2018 The Authors. European Journal of Immunology published by
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(Fig. 5C). In order to investigate whether the differences found
in antigen presentation ability of the four subsets were due to the
lack of MHCI or MHCII expression on their cell surface, spleens
from na¨ıve mice were sorted and loaded with antigenic peptides
(Supporting Information Fig. 5). All four subsets that were loaded
with the MHCI binding peptide OVA8 were fully competent to
activate OTI cells. The APC subsets that were loaded with the
MHCII binding T helper peptide OVA17 were also able to present
in MHCII to OTII cells, although the pDCs and macrophages in a
lower degree. Taken together, these data show that all four APC
subsets take up and store antigen for several days, but there is a
clear functional distinction in their antigen presentation ability.
Discussion
DCs are a heterogeneous cell population in vivo where each subset
has different capacities in antigen-presentation. We have previ-
ously reported that DCs can conserve exogenous protein antigen
in a storage organelle, distinct from MHC class II compartments
or MHCI processing/ loading compartments, for several days that
corresponds with sustained CTL cross-priming in vivo [1]. In the
current study we further investigate the antigen storage and pre-
sentation abilities of APC subsets (CD8α+ DCs, CD8α− DCs, pDCs
and macrophages) in vivo. In contrast to most studies that used in
vitro preformed Ag-Ab immune complexes (IC), we sequentially
injected mice with antibody followed by cognate protein antigen
(i.v.) to allow natural formation of IC in circulation. We show here
for the first time that all APC subsets take up antigen and have the
ability to store antigen for several days in vivo. This corresponds
with long-lasting in vivo antigen presentation to CD8+ and CD4+
T cells and effective cytotoxic T-cell killing of target cells up to a
week after antigen injection. From all APC subsets, CD8α+ DCs
were superior in antigen cross-presentation and showed sustained
CD8+ T-cell activation after isolation. On the other hand, only
CD8α− DCs were able to present antigen to CD4+ T cells sev-
eral days after antigen injection. These results are in line with
other studies that show distinct antigen presentation capacities by
CD8α+ DCs and CD8α− DCs to T cells [6, 7, 9–11]. It had been
suggested that cross-presentation by CD8α− DCs depends on acti-
vating Fcγ receptors (FcγR), since MHCI antigen presentation by
CD8α− DCs was hampered in γ-chain-deficient mice [8]. Cross-
presentation by CD8α+ DCs from γ-chain-deficient mice remained
intact, indicating that activation of CD8α+ DCs is not necessary
for efficient cross-presentation. However, we have recently shown
that complement factor C1q, and not FcγR, plays a major role
in antibody-mediated antigen uptake from blood circulation and
presentation by APCs in vivo [13]. Mice lacking C1q showed no
detectable antigen uptake in APCs and strongly reduced antigen
presentation to CD8+ or CD4+ T cells.
Despite that pDCs and macrophages take up antigen, we
showed no detectable antigen presentation to T cells. Both pDCs
and macrophages have been described as poor antigen cross-
presenting APCs compared to cDCs [14–20]. Several studies have
addressed the contribution of pDCs in cross-priming of CD8+
T cells with different infection models since pDCs are unique in
their ability to produce large amounts of type I interferons (IFN
I) upon viral infections, however no specific role for pDCs was
found in MHCI cross-presentation [21, 22]. pDCs probably play
a more important role in endogenous viral infections or there
still might be unidentified specific antigen targeting routes that
can induce the cross-presentation ability of pDCs. Macrophages
mostly function as the first line of defense against pathogens by
its rapid particle and immune complex removal and degradation
abilities. One study showed that macrophages were able to prime
na¨ıve T cells in vivo by using 10-fold more antigen compared with
DCs [23]. Based on our datawe however feel thatmacrophages are
far less effective in T-cell priming than DCs. Although it has been
suggested that macrophages have more acidic endosomal environ-
ments with many lysosomal proteases that results in faster antigen
degradation compared to DCs [24, 25], we could still detect sim-
ilar amounts of stored protein antigen in splenic macrophages
compared to other DC subsets 3 days after antigen and antibody
injection. Moreover, others have shown that the antigen uptake
capacity does not determine cross-presentation efficiency in APC
subsets [11]. Therefore it is more likely that, at least in this target-
ing system, other mechanisms located downstream from antigen
uptake and storage determine the cross-presentation outcome of
APC subsets.
We have previously demonstrated that the processing of anti-
gen from the storage organelle in DCs involves a cytosolic and
TAP-dependent pathway since inhibiting proteasomal activity or
using TAP deficient DCs almost completely inhibits MHCI cross-
presentation [1]. Therefore, it is presumable that antigens from
the storage compartment are degraded by the proteasome in the
cell cytosol and loaded on MHCI in the ER, although it is not
excluded that peptides, after proteasome degradation, are trans-
ported back into endocytic compartments where they are trimmed
by IRAP and loaded on MHCI as reported by Van Endert and
colleagues [26]. It is still unclear how antigens are transferred
from endosomes into the cytosol for proteasomal degradation.
One study used exogenous cytochrome c, which induces apopto-
sis upon release in the cell cytosol, to show that CD8+ DCs was
the major DC subset reduced by the treatment in vivo [27]. These
data suggest that CD8+ DCs possess a highly efficient mechanism
for endosome-to-cytosol transport compared to other APC subsets.
Some reports suggested Sec61 as the translocator for endosome-
to-cytosol transport of antigens for DC cross-presentation to CD8+
T cells [28, 29], however a more recent study showed the oppo-
site [30]. Others showed that by silencing Sec22b, an ER-resident
SNARE, cross-presentation by DCs is impaired due to antigen
transfer inhibition from phagosomes to the cytosol [31]. Neverthe-
less, it is still not clear which specific translocator onDC endosomal
membranes regulate antigen transportation from endosomes to
the cytosol. Characterizing translocator function might give bet-
ter insight into the different cross-presentation outcome of APC
subsets.
We have shown previously that cell surface MHCI on DCs have
a shorter turnover rate compared to MHCII [1]. Most MHCI-
peptide complexes disappear from the cell surface within 24 h.
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Since the migration of DCs after antigen encountering to the
T-cell zones might take up to several days, this high turnover
rate of MHCI is not beneficial for efficient CD8+ T-cell cross-
presentation [32]. Also the dose of antigen that is expressed on
MHCI needs to exceed the required threshold for effective T-cell
activation. Therefore, long term antigen storage in DCs and sus-
tained antigen display on the DC cell-surface is important to ensure
T-cell cross-priming. Several reports have shown that DCs in vivo
have relative rapid turnover rates [33–35]. It has been suggested
that cDCs in mouse spleen undergo faster turnover and have a
shorter lifespan than pDCs, approximately a half-life of 2 days and
8 days respectively. Some studies suggest that rapid turnover of
cDCs favors the engulfment by other DCs which facilitate antigen
processing and presentation [36, 37]. In regard to our observa-
tions of sustained in vivo antigen presentation of splenic APCs,
the significance of different lifespans of APC subsets may also con-
tribute to modulation of immune control.
In conclusion, we show here for the first time that in vivo DC
subsets can store antigen for several days in storage compartments
and that this contributes to sustained and selective antigen cross-
presentation to CD8+ and CD4+ T cells. Further characterization
of the downstream antigen processing pathways within each APC
subset may reveal why specific subsets are superior in MHCI
cross-presentation or MHCII antigen presentation.
Materials and methods
Mice
All animal experiments in this paper have been approved by the
review board of Leiden University Medical Center. C57BL/6 mice
were purchased from Charles River Laboratories. CD45.1 congenic
mice on C57BL/6 background, OTI mice (CD8+ T-cell transgenic
mice expressing a TCR recognizing the OVA derived Kb associ-
ated epitope SIINFEKL) and OTII mice (CD4+ T-cell transgenic
mice expressing a TCR recognizing the OVA derived Th epitope
ISQAVHAAHAEINEAGR in association with I Ab) were bred and
kept at the LUMC animal facility under SPF conditions. All mice
were used at 8–12 weeks of age.
In vivo formed OVA-IgG complexes
C57BL/6 mice were intravenously injected with 100 μg polyclonal
rabbit anti-OVA IgG (ICN Biomedicals). After 30 min of antibody
circulation, micewere injected intravenously with 5μgOvalbumin
(OVA, Worthington Biochemical Corporation) or OVA conjugated
with Alexa Fluor 647 (Life Technologies). As control antibody,
polyclonal rabbit anti-human papilloma virus (HPV) E6 IgG were
generated in our lab by vaccinating New Zealand rabbits with
recombinant E6 protein.
T-cell proliferation in vivo
Recipient mice received intravenously CFSE-labeled spleen cells
from OTI or OTII mice (purified with CD8 and CD4 T lymphocyte
enrichment kit respectively, BD Biosciences). After 4 days, spleens
from the recipient mice were collected and proliferation of CFSE-
labeled T lymphocytes was analyzed by flow cytometry. OTI cells
were gated as CD8+/ CD90.1+ cells. OTII cells were gated as
CD4+/ CD45.1+ cells.
In vivo cytotoxicity assay
C57BL/6 mice were injected with anti-OVA antibody and OVA
to form OVA-IgG complexes in vivo as described before or only
with OVA. After different time points mice received spleen cells
from OTI mice (CD8+ T-cell enriched) intravenously. 4 days later
Ly5.1+ splenocytes were used at target cells. The target cells were
labeled with 5 μmol/L CFSE and pulsed with OVA peptide SIIN-
FEKL (0.5 μg/mL, 1 h at 37°C), or labeled with 0.5 μmol/L CFSE
and pulsed with the control Db- binding flu-peptide ASNENM-
DAM (1 μg/mL, 1 h at 37°C). The target cells were mixed 1:1
ratio and injected intravenously. Spleen cells and lymph nodes
were isolated the next day and the number of specific CFSEhigh
and control CFSElo Ly5.1+ were measured by flow cytometry.
CD8+/ CD90.1+ OTI cells were stained for effector T-cell markers
CD127 and CD44. The percentage of specific killing is calculated
as follows: (1-(ratio injected mice/ ratio background mice)) ×
100%. Ratio is defined by the number of SIINFEKL CFSEhigh target
cells/ number of control CFSElow target cells. Background mice
are C57BL/6 mice injected with only OTI cells.
Ex vivo antigen presentation
Spleens from C57BL/6 mice with in vivo formed OVA-IgG
complexes or only OVA were isolated at different time points.
APC subsets sorting was performed on BD FACSAria II SORP
(BD Biosciences). The purity of each subset after the sort was
determined by flow cytometry: CD8α+ DCs (86%), CD8α− DCs
(81%), pDCs (50%) and macrophages (67%). Contaminations by
other subsets were less than 1%. Each APC subset (50.000 cells)
was incubated with CFSE labeled and purified OTI (50.000) or
OTII cells (50.000) in a 96 well round bottom plate. CD8+ and
CD4+ T-cell proliferation was measured after 4 days by flow
cytometry. Minimal peptide loading controls were performed
with APC subsets from na¨ıve C57BL/6 mice. After isolation, each
subset was incubated with 100 pg/mL OVA8 (SIINFEKL) or 1
μg/mL OVA17 (ISQAVHAAHAEINEAGR) for 1 h and washed
extensively afterwards. Each subset was then incubated with
either CFSE labeled OTI or OTII cells and T-cell proliferation was
measured by flow cytometry 3 days later.
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Antigen presence in splenic APC subsets
C57BL/6 mice with in vivo formed OVA-IgG complexes or only
OVA (Alexa Fluor 647 labeled, Life Technologies) were sacrificed
at different time points. Spleens were isolated and dissociated with
Liberase (Thermolysin Low, research grade, Roche) for 20 min at
37°C. The antigen presence was measured by the percentage of
Alexa Fluor 647 positive cells and the mean fluorescence intensity
(MFI) within each APC subset. Background levels were determined
by na¨ıve mice without any injections.
In addition, antigen presence in splenic APC subsets was
visualized by confocal scanning laser microscopy. APC subsets
sorting was performed as described before and sorted cells were
incubated for 30 min with Lysotracker (Green DND-26, Ther-
moFisher) at 37°C, washed and transferred to glass bottom dishes
(MatTek coporation, Ashland, USA). Live cells were imaged using
Leica SP5 STED confocal microscope with a 63x objective lens.
Differential interference contrast (DIC) was additionally used
to image cell contrast. Images were acquired by taking optical
slices in 10× magnification and were processed with Leica LAS
AF software. Co-localization was measured by a line scan drawn
on a single optical slice and plotted in histograms. Each arrow
indicates co-localization between OVA and Lysotracker.
Ovalbumin specific mouse IgG generation and transfer
C57BL/6 mice were injected s.c. with 100 μg OVA emulsified in
Incomplete Freund’s Adjuvant (IFA) and boosted 2 weeks later
with 100 μg OVA in IFA. After two weeks, blood was withdrawn
from the lateral tail vein and the presence of mouse anti-OVA
IgG was determined by ELISA. Seropositive C57BL/6 mice were
injected i.v. with 5 μg OVA (Alexa Fluor 647 labeled) and spleen
APCs were analyzed 24 h later for the presence of fluorescent
OVA by flow cytometry. Furthermore, sera from OVA seroposi-
tive C57BL/6 mice were collected and transferred i.v. into na¨ıve
C57BL/6 mice followed by i.v. injection of 5 μg OVA (Alexa Fluor
647 labeled). The presence of fluorescent OVA was measured 24
h later in spleen APCs by flow cytometry.
Quantification of ovalbumin in mouse serum
Na¨ıve C57BL/6 mice were injected i.v. with 100 μg polyclonal
rabbit anti-OVA IgG. After 30 min, mice were injected i.v. with
5 μg OVA (Alexa Fluor 647 labeled). At indicated time points
50 μL blood was withdrawn from the lateral tail vein and serum
was collected. A total of 5 μL serum was mixed with sample
buffer, heated at 95°C for 5 min and loaded on SDS/PAGE.
Fluorescent OVA was quantified directly from the SDS/PAGE gels
by using a Typhoon 9410 Variable mode imager (GE Healthcare
Bio-Sciences) and ImageQuant TL v8.1 software (GE Healthcare
Life Sciences), indicated by relative pixel intensity.
Statistical analysis
Statistical analysis was performed using one-way analysis of vari-
ance (ANOVA) test. Tukey’s post hoc test was performed to correct
for multiple comparisons The following indications are used in all
figures: *p <0.05, **p < 0.01, ***p <0.001, n.s: non-significant.
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